Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of September 2017
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
5 September 2017 07:00 BST
ASTRAZENECA APPOINTS SHERI MCCOY AND
DEBORAH DISANZO TO ITS BOARD
AstraZeneca
today announced that the Board has appointed Sheri McCoy and
Deborah DiSanzo as Non-Executive Directors of AstraZeneca PLC. Ms
McCoy will also become a member of the Audit
Committee.
Ms
McCoy's appointment to the Board and the Audit Committee is
effective 1 October 2017, while Ms DiSanzo's appointment to the
Board is effective 1 December 2017.
Leif
Johansson, Chairman of AstraZeneca, said: "We are delighted to
welcome Sheri McCoy and Deborah DiSanzo to our Board. They are
proven, seasoned executive leaders with experience and knowledge
directly relevant to AstraZeneca's business - Sheri's deep
understanding of the pharmaceutical industry from her many years at
Johnson & Johnson and Deborah's distinguished career in
healthcare and technology with IBM Watson Health and previously
Philips Healthcare. We look forward to their contributions to the
work of the Board of AstraZeneca."
In
relation to the appointments of both Ms McCoy and Ms DiSanzo, no
disclosure obligations arise under paragraphs (2) to (6) of LR
9.6.13 R of the UK Listing Authority's Listing Rules. Details of
directorships to be disclosed under paragraph (1) of LR 9.6.13 R
are included within the biographical details below.
Sheri McCoy - biographical details
Sheri
McCoy is Chief Executive Officer and a Director of Avon Products,
Inc. Since joining the company in April 2012, she has been
responsible for driving new long-term growth initiatives and
advancing Avon as the world's premier direct seller of quality
beauty products.
Prior
to Avon, Ms McCoy had a distinguished 30-year career at Johnson
& Johnson, most recently serving as Vice Chairman of the
Executive Committee, responsible for the Pharmaceuticals and
Consumer business segments that represented more than 60 percent of
the company's revenues. Ms McCoy joined Johnson & Johnson as a
scientist in research and development and subsequently managed
businesses in every major product sector, including consumer,
prescription medicines and medical devices, holding positions
including Worldwide Chairman, Pharmaceuticals Group and Division
President, Consumer. She holds a Bachelor of Science degree in
textile chemistry from the University of Massachusetts in the US; a
Master's degree in chemical engineering from Princeton University
and an MBA from Rutgers University, both in New Jersey,
US.
Ms
McCoy also serves on the boards of New Avon LLC; Catalyst;
Stonehill College, Easton, Massachusetts, US; and FIRST, a
non-profit organisation created to inspire young people's interest
and participation in science and technology.
Deborah DiSanzo - biographical details
Deborah
DiSanzo is the global General Manager for IBM Watson Health, the
business unit founded to achieve IBMs next 'moonshot' aimed at
advancing health at a global scale. She leads a team of 7,000
employees around the world, ranging from medical experts to health
economists to data scientists, user-experience experts and
developers. Under Ms DiSanzo's leadership, Watson Health has
secured relationships with more than 80 collaborators, partners and
clients across healthcare and life sciences. She is widely
recognised as a leading health influencer and is a sought-after
speaker at healthcare and women in technology venues, including the
Forbes Healthcare Summit and Aspen Ideas Festival.
Ms
DiSanzo has a distinguished career working at the intersection of
healthcare and technology. Prior to joining IBM, Ms DiSanzo was
Chief Executive Officer of Philips Healthcare. Previously, she held
management roles at Hewlett-Packard and Apollo Computer. Ms DiSanzo
earned an MBA from Babson College and a Bachelor of Science degree
from Merrimack College, both in Massachusetts, US.
A
dedicated community leader, Ms DiSanzo is currently focused on
domestic and global programmes with organisations including the
World Economic Forum, Project HOPE, and the American Heart
Association. She is also a Director of ReWalk Robotics,
Inc.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular &
Metabolic Diseases and
Respiratory. The Company also is selectively active in the areas of
autoimmunity, neuroscience and infection. AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information, please
visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
|
Media
Relations
|
|
|
|
Esra
Erkal-Paler
|
UK/Global
|
+44 203
749 5638
|
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
|
Matt
Kent
|
UK/Global
|
+44 203
749 5906
|
|
Jacob
Lund
|
Sweden
|
+46 8
553 260 20
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
|
|
|
|
Investor
Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Craig
Marks
|
Finance,
Fixed Income, M&A
|
+44
7881 615 764
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Mitchell
Chan
|
Oncology
|
+1 240
477 3771
|
|
Nick
Stone
|
Respiratory,
Brilinta
|
+44 203
749 5716
|
|
Christer
Gruvris
|
Diabetes;
Autoimmunity, Neuroscience & Infection
|
+44 203
749 5711
|
|
US toll
free
|
|
+1 866
381 7277
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
5
September 2017
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|